Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

CELMoD Approval Brings “Familiar” Dosing Protocols to Multiple Myeloma

31 August 2026 · By · Wire by Fusion42

Published

31 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at cancernetwork.com →

◆ Verified

Fusion42 · 1 September 2026 · Fusion42 review

The FDA accelerated approval of iberdomide (Zenbexus) in combination with daratumumab, hyaluronidase-fihj (Darzalex Faspro), and dexamethasone introduces a novel CELMoD therapy for relapsed/refractory multiple myeloma with dosing protocols similar to immunomodulatory drugs (IMiDs), expected to ease clinical adoption.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face an easier path to integrate CELMoD therapy into your oncology practice due to familiar dosing that accelerates adoption, but you must prepare for new protocols around this more potent anticancer agent.

◆ Coverage

1 source · 31 Aug 2026

◆ Related on Wire

◆ Topics

Biotechcelmodmultiple-myelomafda-approvaloncologycancer-therapy